Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies
Clinical Lymphoma, Myeloma & Leukemia
Hairy cell leukemia (HCL) responds well to purine analogs with an overall median relapse free survival of 11-16 years. Most patients can be retreated with the same or a different purine analog however a subset of patients will become resistant or develop cumulative toxicities. Novel agents such as Vemurafenib (BRAF kinase inhibitor), Bendamustine/Rituximab (BR), Moxetumomab pasudotox (anti CD-22 recombinant immunotoxin) and Ibrutinib have emerging roles in patients with relapsed HCL.
Siddiqui R, Sardar M, Shahzad M, Jose J, Selene I, Shah Z, Qureshi A, Shafqat M, Kashif R, Ahmad M, Mejia-Garcia A, Anwer F. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. Clin Lymphoma Myeloma Leuk. 2021 Jun 24:S2152-2650(21)00237-8. doi: 10.1016/j.clml.2021.06.007. Epub ahead of print. PMID: 34275772.